6 completed. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow Steroid Metabolism, Inborn Errors: new trials by email Literature Review of Steroid Metabolism, Inborn Errors trials Research Report on Steroid Metabolism, Inborn Errors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia Chronocort, Cortef, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 55 | 2022-05-24 | 2026-10-02 |
| Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Chronocort - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Immedica Pharma AB | 76 | 2022-04-01 | 2026-06-18 |
| A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 91 | 2016-08-18 | 2026-10-02 |
| Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Chronocort®, standard glucocorticoid therapy - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 122 | 2016-02-22 | 2026-10-02 |
| The Role of Mineralocorticoid Receptors in Vascular Function Glycyrrhetic Acid, Placebo - Apparent Mineralocorticoid Excess (AME) | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 15 | 2002-02-01 | 2016-10-26 |
| Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Fludrocortisone, Hydrocortisone, Letrozole - Congenital Adrenal Hyperplasia (CAH) | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 66 | 1995-06-08 | 2025-06-12 |
Adrenal Hyperplasia, Congenital (5) · Mineralocorticoid Excess Syndrome, Apparent (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Nutritional and Metabolic Diseases (6) · Adrenal Gland Diseases (5) · Adrenogenital Syndrome (5) · Congenital Abnormalities (5) · Disorders of Sex Development (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Gonadal Disorders (5) · Male Urogenital Diseases (5)
Hydrocortisone (4) · Dexamethasone (1) · Fludrocortisone (1) · Flutamide (1) · Glycyrrhetinic Acid (1) · Letrozole (1) · Prednisolone (1) · Prednisone (1) · Testolactone (1)
Neurocrine UK Limited (3) · Brigham and Women's Hospital (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Immedica Pharma AB (1)
United States (6) · France (2) · Japan (2)
D Merke (1) · Debbie Merke, MD (1) · Deborah P Merke, M.D. (1) · Joshua A Beckman, MD (1)